Pfizer is wrapping up its lucrative goodbye to Haleon, raising approximately $3.3 billion by offloading its remaining 7.3% ...

Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifu ...

RANKL/osteoprotegerin/RANK signaling regulates bone resorption and ... Dishevelled; Fz: Frizzled; GSK: Glycogen synthase kinase; LEF: Lymphoid enhancer factor; sFRP: Secreted frizzled related ...

The stock of GlaxoSmithKline Pharmaceuticals (GSK Pharma) hit a three-month high of ₹2,640 a share as it surged 5 per cent on Monday before closing at ₹2,638. During the past seven trading days, the ...

GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine sales falling, some market participants say it may draw in activist ...

The approvals are supported by two phase 3 clinical trial programs ... As a blocker of IL-31 signaling, nemolizumab is an especially welcome addition to the systemic therapy space for both ...

The shares of GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma) jumped over 15 percent to trade at Rs 2,684 apiece on February 18, extending gains for the second straight session after releasing ...

The Food and Drug Administration on Friday gave a green light to a new meningococcal vaccine from GSK. Dubbed Penmenvy, the “5-in-1” shot is approved for people aged 10 through 25 years old and ...

GSK Pharma delivered a better-than-expected performance in Q3, largely driven by robust volume growth in the general medicine segment and a continued scale-up in vaccine offtake. Notably, the company ...